Filing and period
Important identification mismatch: The request names Neurogene Inc., but the supplied Form 10-K is for Aquinox Pharmaceuticals, Inc. It covers the fiscal year ended December 31, 2014, not a standalone quarterly filing. The filing was signed March 16, 2015. The summary below describes the supplied Aquinox filing.
Business context
Aquinox was a clinical-stage biotechnology company developing AQX-1125, an oral SHIP1 activator intended to treat inflammatory diseases. At year-end, it was conducting Phase 2 trials in COPD, bladder pain syndrome/interstitial cystitis (BPS/IC), and atopic dermatitis (AD). It had no approved products and had generated no revenue.
Financial performance and position
| Metric | 2014 | 2013 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $18.1 million | $7.6 million |
| General and administrative expense | $4.3 million | $1.8 million |
| Total operating expenses | $22.4 million | $9.4 million |
| Net loss | $24.0 million | $8.7 million |
| Operating cash used | $17.8 million | $7.9 million |
| Cash, cash equivalents and investments | $41.1 million | $13.8 million |
| Working capital | $34.1 million | $12.7 million |
| Bank debt | None at year-end | $2.3 million |
Net loss attributable to common stockholders was $23.8 million in 2014, or $2.75 per share, compared with $14.9 million, or $49.52 per share, in 2013; the per-share comparison is affected by the 2014 IPO, share conversion, and change in weighted-average shares. No revenue was reported, so revenue margins are not meaningful. The company reported a $24.0 million accumulated deficit and $36.1 million of stockholders’ equity at year-end.
Fourth-quarter 2014 operating expenses were $7.8 million and net loss was $8.1 million. These compared with fourth-quarter 2013 operating expenses of $3.3 million and net loss of $3.5 million.
Material changes and financing
- R&D spending rose 138% year over year, principally as the COPD and BPS/IC Phase 2 trials advanced; manufacturing/formulation and preclinical costs also increased.
- G&A increased following the March 2014 IPO and as a result of public-company costs, additional personnel, insurance, and professional services.
- The March 2014 IPO raised $53.1 million gross and approximately $47.3 million net. The company reported using about $6.8 million of IPO proceeds through year-end.
- Operating cash use increased to $17.8 million. Financing cash flow was $45.3 million, mainly reflecting IPO proceeds; investing cash use was $23.6 million as funds were placed in liquid securities.
- The $2.5 million Silicon Valley Bank loan was repaid in March 2014. The company had no bank loan outstanding at year-end.
Outlook, commentary and risks
- Management expected existing capital resources to fund operations for at least 12 months from the filing, while stating that substantial additional financing would likely be needed. Spending and losses were expected to rise as trials progressed.
- The approximately 400-patient COPD Flagship trial and 69-patient BPS/IC Leadership trial had completed enrollment; top-line results were expected near mid-2015. The approximately 50-patient AD Kinship trial began enrollment in December 2014, with initial results anticipated in the first quarter of 2016.
- Management delayed a planned fourth Phase 2 trial in chronic rhinosinusitis to prioritize the Flagship and Leadership trials. It also intended to advance a next-generation SHIP1 candidate into clinical trials by 2016.
- Earlier clinical studies reported generally mild-to-moderate adverse events, most often gastrointestinal. The filing also disclosed severe gastrointestinal ulcerations and ocular-lens effects in animal toxicology studies; whether these would occur in humans was uncertain.
- Development risks include failure of Phase 2 results, an unvalidated SHIP1 target, uncertainty about the COPD trial endpoint’s acceptability for later-stage trials, clinical/regulatory delays, and reliance on contract research organizations and manufacturers. The filing noted a laboratory processing error that prevented efficacy measurement for the 200 mg arm of an earlier COPD proof-of-concept study.
- Other material risks include no product revenue, future financing and dilution needs, foreign-exchange exposure (no hedging), competitive and reimbursement pressures, intellectual-property uncertainty, and dependence on third parties. A $3.0 million Canadian-dollar milestone could become payable if the board commits resources to advance AQX-1125 into Phase 3.
- Deloitte issued an unqualified audit opinion on the financial statements. Management disclosed significant deficiencies in internal controls identified during the audit; the filing did not include management’s internal-control effectiveness assessment because of the new-public-company transition period. Disclosure controls were deemed effective.
Investor verification priorities
- Confirm the intended issuer: the supplied filing is Aquinox Pharmaceuticals, not Neurogene Inc.
- Review subsequent filings and trial disclosures for the COPD and BPS/IC results expected in 2015, and the progress and outcome of the AD trial.
- Assess cash burn, remaining liquidity, and financing raised after December 31, 2014 against management’s stated 12-month runway.
- Check clinical safety updates, particularly in light of animal toxicology findings and gastrointestinal tolerability.
- Verify the status of the COPD endpoint and FDA feedback on requirements for Phase 3 development.
- Review remediation of reported internal-control deficiencies and future funding, dilution, and milestone obligations.